These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20237039)

  • 1. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial.
    Abraham A; Nichol G; Williams KA; Guo A; deKemp RA; Garrard L; Davies RA; Duchesne L; Haddad H; Chow B; DaSilva J; Beanlands RS;
    J Nucl Med; 2010 Apr; 51(4):567-74. PubMed ID: 20237039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial.
    D'Egidio G; Nichol G; Williams KA; Guo A; Garrard L; deKemp R; Ruddy TD; DaSilva J; Humen D; Gulenchyn KY; Freeman M; Racine N; Benard F; Hendry P; Beanlands RS;
    JACC Cardiovasc Imaging; 2009 Sep; 2(9):1060-8. PubMed ID: 19761983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease.
    Mc Ardle B; Shukla T; Nichol G; deKemp RA; Bernick J; Guo A; Lim SP; Davies RA; Haddad H; Duchesne L; Hendry P; Masters R; Ross H; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; Mielniczuk L; DaSilva JN; Garrard L; Wells GA; Beanlands RS;
    Circ Cardiovasc Imaging; 2016 Sep; 9(9):. PubMed ID: 27609816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).
    Beanlands RS; Nichol G; Huszti E; Humen D; Racine N; Freeman M; Gulenchyn KY; Garrard L; deKemp R; Guo A; Ruddy TD; Benard F; Lamy A; Iwanochko RM;
    J Am Coll Cardiol; 2007 Nov; 50(20):2002-12. PubMed ID: 17996568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.
    Shukla T; Nichol G; Wells G; deKemp RA; Davies RA; Haddad H; Duchesne L; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; DaSilva J; Garrard L; Guo A; Chen L; Beanlands RS
    Can J Cardiol; 2012; 28(1):54-61. PubMed ID: 22138342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET.
    Zhang X; Liu XJ; Wu Q; Shi R; Gao R; Liu Y; Hu S; Tian Y; Guo S; Fang W
    J Nucl Med; 2001 Aug; 42(8):1166-73. PubMed ID: 11483675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods.
    Beanlands R; Nichol G; Ruddy TD; deKemp RA; Hendry P; Humen D; Racine N; Ross H; Benard F; Coates G; Iwanochko RM; Fallen E; Wells G;
    Control Clin Trials; 2003 Dec; 24(6):776-94. PubMed ID: 14662282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease.
    Wu YW; Tadamura E; Yamamuro M; Kanao S; Marui A; Tanabara K; Komeda M; Togashi K
    J Nucl Med; 2007 Jul; 48(7):1096-103. PubMed ID: 17607039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function.
    Beanlands RS; Ruddy TD; deKemp RA; Iwanochko RM; Coates G; Freeman M; Nahmias C; Hendry P; Burns RJ; Lamy A; Mickleborough L; Kostuk W; Fallen E; Nichol G;
    J Am Coll Cardiol; 2002 Nov; 40(10):1735-43. PubMed ID: 12446055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment.
    Santana CA; Faber TL; Soler-Peter M; Sanyal R; Esteves FP; Ornelas M; Folks RD; Verdes L; Santana LF; Candell-Riera J; Garcia EV
    Nucl Med Commun; 2008 Nov; 29(11):970-81. PubMed ID: 18836375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging.
    Beanlands RS; Hendry PJ; Masters RG; deKemp RA; Woodend K; Ruddy TD
    Circulation; 1998 Nov; 98(19 Suppl):II51-6. PubMed ID: 9852880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial perfusion reserve after a PET-driven revascularization procedure: a strong prognostic factor.
    Slart RH; Zeebregts CJ; Hillege HL; de Sutter J; Dierckx RA; van Veldhuisen DJ; Zijlstra F; Tio RA
    J Nucl Med; 2011 Jun; 52(6):873-9. PubMed ID: 21571798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction.
    Schinkel AF; Poldermans D; Rizzello V; van Domburg RT; Valkema R; Elhendy A; Biagini E; Krenning EP; Simoons ML; Bax JJ
    J Nucl Med; 2006 Jan; 47(1):68-73. PubMed ID: 16391189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction.
    Tarakji KG; Brunken R; McCarthy PM; Al-Chekakie MO; Abdel-Latif A; Pothier CE; Blackstone EH; Lauer MS
    Circulation; 2006 Jan; 113(2):230-7. PubMed ID: 16391157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy.
    Santana CA; Shaw LJ; Garcia EV; Soler-Peter M; Candell-Riera J; Grossman GB; Krawczynska EG; Faber TL; Ribera A; Vaccarino V; Halkar R; Di Carli MF
    J Nucl Cardiol; 2004; 11(5):542-50. PubMed ID: 15472639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease.
    vom Dahl J; Altehoefer C; Sheehan FH; Buechin P; Schulz G; Schwarz ER; Koch KC; Uebis R; Messmer BJ; Buell U; Hanrath P
    J Nucl Med; 1997 May; 38(5):742-8. PubMed ID: 9170439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET for detecting myocardial viability: validation of 3D data acquisition.
    Brogsitter C; Grüning T; Weise R; Wielepp P; Lindner O; Körfer R; Burchert W
    J Nucl Med; 2005 Jan; 46(1):19-24. PubMed ID: 15632028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of myocardial viability and coronary revascularization on clinical outcome and prognosis: a follow-up study of 161 patients with coronary heart disease].
    vom Dahl J; Altehoefer C; Büchin P; Sheehan FH; Schwarz ER; Koch KC; Schulz G; Uebis R; Schöndube F; Messmer BJ; Büll U; Hanrath P
    Z Kardiol; 1996 Nov; 85(11):868-81. PubMed ID: 9064949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of QGS and 4D-MSPECT for quantification of left ventricular volumes and ejection fraction from gated 18F-FDG PET: comparison with cardiac MRI.
    Schaefer WM; Lipke CS; Nowak B; Kaiser HJ; Reinartz P; Buecker A; Krombach GA; Buell U; Kühl HP
    J Nucl Med; 2004 Jan; 45(1):74-9. PubMed ID: 14734676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of F-18 FDG positron emission tomography (PET) in the assessment of myocardial viability.
    Ghesani M; Depuey EG; Rozanski A
    Echocardiography; 2005 Feb; 22(2):165-77. PubMed ID: 15693785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.